Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
复制标题
DOI：
10.1080/14760584.2016.1218762
复制
发表时间：
2017-01
影响因子：
6.2
通讯作者：
Sampson JH
中科院分区：
文献类型：
--
作者：
Schaller TH;Sampson JH
胶质母细胞瘤是成人中最常见的原发性脑肿瘤，预后仍然很差，中位生存期约为15 - 17个月。本文综述了胶质母细胞瘤免疫治疗领域的最新进展。树突状细胞疫苗免疫疗法的最新进展在临床试验中显示出令人鼓舞的结果，并有望延长患者的生存期。在这份报告中，我们讨论了目前的科学知识，树突状细胞（DC）疫苗，包括方法分化，启动和注射树突状细胞，以实现最大的抗肿瘤疗效胶质母细胞瘤。将这些发现与最近完成的和目前正在进行的胶质母细胞瘤临床试验进行比较。与传统的DC疫苗相比，新的方法如"fastDCs"和靶向DC的疫苗在体内可能提供更有效的治疗，并且已经进入临床。最后，我们讨论了胶质母细胞瘤免疫抑制引起的T细胞功能障碍的挑战，以及它们如何影响树突状细胞疫苗接种方法。
Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Recent advances in dendritic cell vaccination immunotherapy are showing encouraging results in clinical trials and promise to extend patient survival. In this report we discuss current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy in glioblastoma. These findings are compared to recently completed and currently ongoing glioblastoma clinical trials. Novel methods such as ‘fastDCs’ and vaccines targeting DCs in-vivo may offer more effective treatment when compared to traditional DC vaccines and have already entered the clinic. Finally, we discuss the challenges of T-cell dysfunctions caused by glioblastoma immunosuppression and how they affect dendritic cell vaccinations approaches.